Which transition risk is associated with buprenorphine when switching from a full opioid agonist?

• A. Sedation.
• B. Hyperalgesia.
• C. Precipitated withdrawal.
• D. Hypotension.

Answer: (C)

The key idea is how buprenorphine’s pharmacology affects receptors when you switch someone from a full opioid agonist. Buprenorphine binds mu opioid receptors with very high affinity but only partially activates them. When a full agonist is still occupying receptors, introducing buprenorphine can displace the agonist but doesn’t provide the same level of receptor signaling, so the body experiences a sudden drop in opioid effect. That abrupt decrease manifests as precipitated withdrawal.

This is why precipitated withdrawal is the expected transition risk: it specifically arises from the combination of strong receptor binding and partial agonism, not from general side effects like sedation or hypotension, and not from hyperalgesia in the context of the switch. Practically, clinicians manage this by tapering the full agonist to a mild withdrawal state before starting buprenorphine or using gradual, low-dose initiation (microdosing) to avoid a sudden displacement.